PMID- 16131571
OWN - NLM
STAT- MEDLINE
DCOM- 20060106
LR  - 20240316
IS  - 0006-4971 (Print)
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 106
IP  - 13
DP  - 2005 Dec 15
TI  - Autologous and allogeneic stem cell transplantations for poor-risk chronic 
      lymphocytic leukemia.
PG  - 4389-96
AB  - We report here on the long-term follow-up on 162 patients with high-risk chronic 
      lymphocytic leukemia (CLL) who have undergone hematopoietic stem cell 
      transplantation (SCT) at a single center from 1989 to 1999. Twenty-five patients 
      with human leukocyte antigen (HLA)-matched sibling donors underwent 
      T-cell-depleted allogeneic SCT, and 137 patients without HLA-matched sibling 
      donors underwent autologous SCT. The 100-day mortality was 4% for both groups, 
      but later morbidity and mortality were negatively affected on outcome. 
      Progression-free survival was significantly longer following autologous than 
      allogeneic SCT, but there was no difference in overall survival and no difference 
      in the cumulative incidence of disease recurrence or deaths without recurrence 
      between the 2 groups. At a median follow-up of 6.5 years there is no evidence of 
      a plateau of progression-free survival. The majority of patients treated with 
      donor lymphocyte infusions after relapse responded, demonstrating a significant 
      graft-versus-leukemia effect in CLL. From these findings we have altered our 
      approach for patients with high-risk CLL and are currently exploring the role of 
      related and unrelated allogeneic SCT following reduced-intensity conditioning 
      regimens.
FAU - Gribben, John G
AU  - Gribben JG
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 
      john.gribben@cancer.org.uk
FAU - Zahrieh, David
AU  - Zahrieh D
FAU - Stephans, Katherine
AU  - Stephans K
FAU - Bartlett-Pandite, Lini
AU  - Bartlett-Pandite L
FAU - Alyea, Edwin P
AU  - Alyea EP
FAU - Fisher, David C
AU  - Fisher DC
FAU - Freedman, Arnold S
AU  - Freedman AS
FAU - Mauch, Peter
AU  - Mauch P
FAU - Schlossman, Robert
AU  - Schlossman R
FAU - Sequist, Lecia V
AU  - Sequist LV
FAU - Soiffer, Robert J
AU  - Soiffer RJ
FAU - Marshall, Blossom
AU  - Marshall B
FAU - Neuberg, Donna
AU  - Neuberg D
FAU - Ritz, Jerome
AU  - Ritz J
FAU - Nadler, Lee M
AU  - Nadler LM
LA  - eng
GR  - CA81534/CA/NCI NIH HHS/United States
GR  - P01AI29530/AI/NIAID NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20050830
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Immunoglobulin Heavy Chains)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Disease Progression
MH  - Female
MH  - Follow-Up Studies
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Immunoglobulin Heavy Chains/genetics
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/pathology/*surgery
MH  - Male
MH  - Middle Aged
MH  - Mutation/genetics
MH  - Prognosis
MH  - Recurrence
MH  - Risk Factors
MH  - Survival Rate
MH  - Transplantation, Homologous
MH  - Treatment Outcome
PMC - PMC1895235
EDAT- 2005/09/01 09:00
MHDA- 2006/01/07 09:00
PMCR- 2006/12/15
CRDT- 2005/09/01 09:00
PHST- 2005/09/01 09:00 [pubmed]
PHST- 2006/01/07 09:00 [medline]
PHST- 2005/09/01 09:00 [entrez]
PHST- 2006/12/15 00:00 [pmc-release]
AID - S0006-4971(20)67760-6 [pii]
AID - 4389 [pii]
AID - 10.1182/blood-2005-05-1778 [doi]
PST - ppublish
SO  - Blood. 2005 Dec 15;106(13):4389-96. doi: 10.1182/blood-2005-05-1778. Epub 2005 
      Aug 30.